Search results for "PERFORMANCE"

showing 10 items of 4457 documents

<p>Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice</p>

2019

Background Several trials evaluated the role of intensive regimens, made of triplet chemotherapies plus bevacizumab, as first-line treatment for patients with metastatic colorectal cancer (mCRC). We previously reported, in a Phase II prospective study, the efficacy and the tolerability of FIrB/FOx regimen, reporting interesting results in terms of received dose intensities (rDIs) and safety. Methods We reported a retrospective update of 85 patients treated with FIrB/FOx, an intensive regimen of 5-fluorouracil, bevacizumab, and weekly alternate irinotecan and oxaliplatin, to confirm its feasibility in "real life". Subgroup analyses were performed, particularly among patients treated with sta…

0301 basic medicineOncologymedicine.medical_specialtyBevacizumabPerformance statusbusiness.industryNeutropeniamedicine.diseaseOxaliplatinIrinotecan03 medical and health sciencesRegimen030104 developmental biology0302 clinical medicineOncologyTolerability030220 oncology & carcinogenesisInternal medicinemedicinePharmacology (medical)businessProspective cohort studymedicine.drugOncoTargets and Therapy
researchProduct

Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence.

2018

Abstract Hepatocellular carcinoma (HCC) is the most common primary liver cancer, representing the sixth leading cause of cancer and the third leading cause of cancer-related mortality. Patient stratification and treatment allocation are based on tumor stage, liver function, and performance status. According to the Barcelona Clinic Liver Cancer (BCLC) staging system, transarterial chemoembolization (TACE) is the first-line treatment for patients with intermediate stage HCC, including those with large or multinodular HCC, well-preserved liver function, and no cancer-related symptoms or evidence of vascular invasion or extrahepatic spread. Two TACE techniques have been used since 2004, convent…

0301 basic medicineOncologymedicine.medical_specialtyCarcinoma Hepatocellular03 medical and health sciences0302 clinical medicineInternal medicineCarcinomamedicineHumansRadiology Nuclear Medicine and imagingStage (cooking)Chemoembolization TherapeuticPerformance statusbusiness.industryLiver NeoplasmsCancerGeneral Medicinemedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisHepatocellular carcinomaLipiodolLiver functionLiver cancerbusinessmedicine.drugCancer treatment reviews
researchProduct

Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection

2018

The identification of reliable predictive biomarkers of efficacy or resistance to immune-oncology (I–O) agents is a major issue for translational research and clinical practice. However, along with PDL1 and molecular features other clinical, radiological and laboratory factors can be considered for the selection of those patients who would not be the best candidate for immune-checkpoint inhibitors (ICPIs). We examined these factors, emerging from the results of currently available studies in non-small cell lung cancer (NSCLC), aiming to provide a useful and manageable tool which can help Oncologists in their everyday clinical practice. A thorough patient evaluation and close clinical monito…

0301 basic medicineOncologymedicine.medical_specialtyLung NeoplasmsImmune-checkpoint inhibitorSettore MED/06 - Oncologia MedicaImmune-checkpoint inhibitorsBiomarkers; Immune-checkpoint inhibitors; Immune-oncology; Non-small cell lung cancer; Predictive factors; Antibodies Monoclonal; B7-H1 Antigen; Biomarkers; CTLA-4 Antigen; Carcinoma Non-Small-Cell Lung; Humans; Immunotherapy; Lung Neoplasms; Patient Selection; Hematology; OncologyAntibodiesB7-H1 Antigen03 medical and health sciences0302 clinical medicineNon-small cell lung cancerCarcinoma Non-Small-Cell LungInternal medicineMonoclonalmedicineHumansCTLA-4 AntigenNeutrophil to lymphocyte ratioNon-Small-Cell LungLung cancerHepatitisPerformance statusbusiness.industryPatient SelectionCarcinomaInterstitial lung diseaseAntibodies MonoclonalBronchiolitis obliterans organizing pneumoniaBiomarkerHematologymedicine.diseaseBiomarkers; Immune-checkpoint inhibitors; Immune-oncology; Non-small cell lung cancer; Predictive factors; Hematology; OncologyClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisImmunotherapyPredictive factorbusinessBiomarkersImmune-oncologyPredictive factorsProgressive diseaseCritical Reviews in Oncology/Hematology
researchProduct

Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized pha…

2017

Abstract Objectives To determine predictive/prognostic factors for patients with metastatic breast cancer (MBC) receiving first-line monochemotherapy using biomarker analysis and geriatric assessment (GA). Materials and Methods Karnofsky Performance Status (KPS) and GA as clinical parameters, and prognostic inflammatory and nutritional index (PINI), and Glasgow prognostic score (GPS) as biomarkers were analyzed for association with clinical outcome within the randomized phase III PEg-LIposomal Doxorubicin vs. CApecitabin iN MBC (PELICAN) trial of first-line pegylated liposomal doxorubicin (PLD) or capecitabine. Results Of 210 patients, 38% were > 65 years old. GA (n = 152) classified 74% as…

0301 basic medicineOncologymedicine.medical_specialtyMultivariate analysisAnthracyclinemedicine.medical_treatmentBreast NeoplasmsPolyethylene GlycolsCapecitabine03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansDoxorubicinKarnofsky Performance StatusGeriatric AssessmentCapecitabineAgedChemotherapyFrailtybusiness.industryAge FactorsGeriatric assessmentMiddle Agedmedicine.diseaseMetastatic breast cancer030104 developmental biologyTreatment OutcomeOncologyDoxorubicin030220 oncology & carcinogenesisDisease ProgressionBiomarker (medicine)FemaleGeriatrics and GerontologybusinessBiomarkersmedicine.drugJournal of geriatric oncology
researchProduct

5-Fluorouracil and recombinant alpha interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study

1990

A dose optimization study was carried out with the aim of identifying the maximally tolerated dose of recombinant alpha interferon-2a (raIFN-2a) in combination with 5-fluorouracil (5FU). 5FU was given at the dose of 750 mg/m2 over a 4-hour infusion on day 1- - greater than 5 followed by 750 mg/m2 weekly i.v. bolus. Recombinant aIFN-2a was started at 3 x 10(6) IU subcutaneously three times/week. 12 patients with advanced colorectal carcinoma were included in the study. 10 patients had previously received chemotherapy for advanced disease. Severe fatigue, most likely attributable to rIFN, was the dose-limiting toxicity. The dosage of raIFN-2a could not be further escalated above 12 x 10(6) IU…

0301 basic medicineOncologymyalgiamedicine.medical_specialtymedicine.medical_treatmentInjections Subcutaneous030106 microbiologyAlpha interferonInterferon alpha-2Gastroenterology03 medical and health sciences0302 clinical medicineBolus (medicine)Internal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansPharmacology (medical)PharmacologyChemotherapyPerformance statusbusiness.industryCarcinomaInterferon-alphamedicine.diseaseRecombinant ProteinsInfectious DiseasesOncologyFluorouracil030220 oncology & carcinogenesisToxicityFluorouracilmedicine.symptombusinessColorectal Neoplasmsmedicine.drug
researchProduct

Development of an Analytical Assay for Electrochemical Detection and Quantification of Protein-Bound 3-Nitrotyrosine in Biological Samples and Compar…

2020

Reactive oxygen and nitrogen species (RONS) cause oxidative damage, which is associated with endothelial dysfunction and cardiovascular disease, but may also contribute to redox signaling. Therefore, their precise detection is important for the evaluation of disease mechanisms. Here, we compared three different methods for the detection of 3-nitrotyrosine (3-NT), a marker of nitro-oxidative stress, in biological samples. Nitrated proteins were generated by incubation with peroxynitrite or 3-morpholino sydnonimine (Sin-1) and subjected to total hydrolysis using pronase, a mixture of different proteases. The 3-NT was then separated by high performance liquid chromatography (HPLC) and quantifi…

0301 basic medicinePhysiologyClinical BiochemistryDot blotmitochondrial superoxidePronase030204 cardiovascular system & hematologymedicine.disease_causeBiochemistryHigh-performance liquid chromatographyArticleperoxynitritePeroxynitrite03 medical and health sciences0302 clinical medicineProtein-bound 3-nitrotyrosinemedicineoxidative stressBovine serum albuminMolecular Biologychemistry.chemical_classificationDetection limitReactive oxygen speciesChromatographyHPLC with electrochemical detectionbiologylcsh:RM1-950Cell Biology3. Good health030104 developmental biologylcsh:Therapeutics. PharmacologychemistryOxidative stressbiology.proteinprotein-bound 3-nitrotyrosineOxidative stressEx vivoMitochondrial superoxide
researchProduct

Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell l…

2019

Abstract Objectives To evaluate the effect on quality of life (QOL) of the addition of cisplatin to single-agent chemotherapy in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC) enrolled in two parallel phase 3 trials, MILES-3 and MILES-4. Patients and methods Advanced NSCLC pts, >70 years old, performance status (PS) 0–1, were eligible. Patients were randomly assigned to chemotherapy without or with cisplatin. EORTC QLQ C30 and LC13 questionnaires were planned at baseline, end of cycle 1 and end of cycle 2 in both trials and were used for joint QOL analysis. Trial-specific data including questionnaires at non-shared time-points were used for additional ana…

0301 basic medicinePulmonary and Respiratory MedicineQuality of lifeMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsNauseamedicine.medical_treatmentRandomizedNSCLCPhase 303 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineSurveys and QuestionnairesCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSurveys and QuestionnaireLung cancerAgedNeoplasm StagingCisplatinAged 80 and overChemotherapyAntineoplastic Combined Chemotherapy ProtocolPerformance statusbusiness.industryAlopeciamedicine.diseaseDysphagiaLung Neoplasm030104 developmental biologyTreatment OutcomeOncology030220 oncology & carcinogenesisVomitingStomatitis AphthousFemalemedicine.symptomCisplatinbusinessElderly patientStomatitis Aphthoumedicine.drugHuman
researchProduct

Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performance.

2018

Cell-based assays to monitor antigen-specific T-cell responses are characterized by their high complexity and should be conducted under controlled conditions to lower multiple possible sources of assay variation. However, the lack of standard reagents makes it difficult to directly compare results generated in one lab over time and across institutions. Therefore TCR-engineered reference samples (TERS) that contain a defined number of antigen-specific T cells and continuously deliver stable results are urgently needed. We successfully established a simple and robust TERS technology that constitutes a useful tool to overcome this issue for commonly used T-cell immuno-assays. To enable users t…

0301 basic medicineRNA StabilityComputer scienceT cellPerformanceCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]RNA StabilityT-LymphocytesImmunologyCell Culture TechniquesComputational biology03 medical and health sciences0302 clinical medicineAll institutes and research themes of the Radboud University Medical CenterHigh complexityValidationHLA-A2 AntigenmedicineImmunology and AllergyHumansImrnunoguidingRNA MessengerCell EngineeringT-cell assaysReceptors Chimeric AntigenImmunomagnetic SeparationElectroporationT-cell receptorRNAReference StandardsStandardizationImmunomonitoring030104 developmental biologymedicine.anatomical_structureElectroporationBlood Buffy CoatFeasibility StudiesBiological Assay030215 immunologyJournal of immunological methods
researchProduct

Performance and risk in the Brazilian banking industry

2021

Andres J. Picazo-Tadeo aknowledges the financial support from the Generalitat Valenciana (project PROMETEO 2018/102).

0301 basic medicineRiskPerformanceCommercial and investment banksSample (statistics)Outcome (game theory)Investment banking03 medical and health sciences0302 clinical medicineData envelopment analysisProduction (economics)lcsh:Social sciences (General)lcsh:Science (General)Directional distance functionsIndustrial organizationMultidisciplinarybusiness.industryBrazilian banking industryBanking industryTechnical performance030104 developmental biologyData Envelopment AnalysisDirectional distance functionlcsh:H1-99business030217 neurology & neurosurgeryResearch Articlelcsh:Q1-390Heliyon
researchProduct

Fast UPLC/PDA determination of squalene in Sicilian P.D.O. pistachio from Bronte: Optimization of oil extraction method and analytical characterizati…

2017

Abstract A fast reversed-phase UPLC method was developed for squalene determination in Sicilian pistachio samples that entry in the European register of the products with P.D.O. In the present study the SPE procedure was optimized for the squalene extraction prior to the UPLC/PDA analysis. The precision of the full analytical procedure was satisfactory and the mean recoveries were 92.8 ± 0.3% and 96.6 ± 0.1% for 25 and 50 mg L−1 level of addition, respectively. Selected chromatographic conditions allowed a very fast squalene determination; in fact it was well separated in ∼0.54 min with good resolution. Squalene was detected in all the pistachio samples analyzed and the levels ranged from 5…

0301 basic medicineSqualeneResolution (mass spectrometry)Settore CHIM/10 - Chimica Degli AlimentiUplc pda01 natural sciencesHigh-performance liquid chromatographyAnalytical Chemistry03 medical and health sciencesSqualenechemistry.chemical_compoundLimit of DetectionNutsPlant OilsSicilySqualene; pistachio (Pistacia vera L.); Food analysis; Green pistachio Bronte (P.D.O.); UPLC/PDA analysis030109 nutrition & dieteticsChromatographyChemistryPlant Extracts010401 analytical chemistryExtraction (chemistry)Reproducibility of ResultsGeneral MedicineSqualene pistachio (Pistacia vera L.) food analysis Green Pistachio Bronte (P.D.O.) UPLC/PDA analysis.Squalene pistachio (Pistacia vera L.) Food analysis Green pistachio Bronte (P.D.O.) UPLC/PDA analysis0104 chemical sciencesPistaciaExtraction methodsFood AnalysisFood Science
researchProduct